Validating imaging biomarkers
New imaging biomarkers are helping radiology to play a greater role in new drug developments.
New imaging biomarkers are helping radiology to play a greater role in new drug developments.
EKF Diagnostics, worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays, has announced the launch of a new division to focus on molecular and companion diagnostics.
MRI has become the gold standard for many indications in cardiac imaging, apart from imaging the coronary arteries. For function and morphology assessment, MRI is the leading technology. A further advance into as yet unknown territory is myocardial imaging aided by one of the first integrated 3-Tesla PET/MR systems currently used at the Institute of Radiology, Essen University Hospital,…
‘We need an ECG for Sepsis,’ urged Professor Konrad Reinhart during this year’s Anaesthesiology and Intensive Care Medicine (HAI) Congress in Berlin.
Dr Peter Choyke, Chief of the Molecular Imaging Programme at the National Cancer Institute in Bethesda, USA, believes that new tracers will have an evolving role to play and represent an exciting development in the imaging of cancers.
Although most nuclear medical examinations using SPECT (single photon emission computed tomography) take place beyond hospitals, two to three times more SPECT exams than PET-CT exams are carried out within hospitals.
UK researchers are working on a new MRI technique called hyperpolarised MRI – or Dynamic Nuclear Polarisation (DNP) – that can utilise more of the available nuclei than traditional MRI, helping to overcome some of its limitations by increasing sensitivity 10,000-fold or more. DNP is part of a longer-term aim to improve cancer mortality with the help of novel cancer imaging tools.
Radiology constantly evolves. There are technical advances in terms of the capabilities of various modalities, greater clarity from contrast agents that are also safer for patients, and innovation in techniques that gains even greater performance from existing equipment, or enables further development.
GE Healthcare announced today its plans to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of biopharmaceuticals and for cancer research.
2011 brought a second year for European and US scientists to meet up at the Annual Scientific Symposium on Ultra High Field Magnetic Resonance, held at the Max Delbrück Centre for Molecular Medicine Berlin-Buch (MDC), Germany, to present and discuss their recent findings. Along with technical improvements, the main issues of the one-day gathering were cardiac, cerebral and molecular MR imaging.…
PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer's disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples.
Research introduced at SNM’s 58th Annual Meeting may lead to much-needed cardiovascular disease screening for diabetic patients at risk of ischemic heart disease, a disorder marked by significantly reduced blood flow in the heart. Ischemia of the myocardium, or cardiac muscle, can signal diminished oxygenation of the heart tissue and trigger a heart attack if left untreated.
Biomarkers – mainly defined as surrogates serving as indicators for specific biological states – play an ever-increasing role in neuroscience and especially in the management of multiple sclerosis, scientists reported today at the 21st Meeting of the European Neurological Society (ENS) in Lisbon. In analyzing gene expression patterns, immunological changes and imaging abnormalities,…
ENCITE experts are very pleased to meet the imaging community at the European Molecular Imaging Meeting (EMIM) 2011 in Leiden/NL. The congress brings together top European scientists from various disciplines working in diverse fields of molecular imaging to discuss latest research discoveries and possible translations into medical practice.
Medical imaging has recently advanced so rapidly that it should halt. Applying more power to computed tomography (CT) and magnetic resonance imaging (MRI) scanners is becoming too dangerous for patients and healthcare workers. Magnets for the next-generation MRIs are so powerful that they must be moved to a separate building on hospital campuses, while CT radiation levels have risen to alarming…
Although developments in molecular imaging still do not reach the high expectations placed upon them, the change in imaging is very obvious. Having been limited to the imaging of morphology, nowadays information on tissue characteristics, blood vessels or the metabolic behaviour of tumours provide many more insights, for example into response behaviour.
Breast cancer can develop very differently in different women. Researchers in Norway are improving breast cancer diagnostics and treatment by identifying the various tumour types. The objective is to find out as much as possible about the various tumour types so that each patient can receive precisely the right treatment at the right time.
Molecular imaging (MI) is reported as an increasingly important diagnostic field for radiologists to focus on. However, molecular imaging should not be considered a new discipline that only adds to today’s clinical practice, or might even replace the traditional, more morphology-oriented diagnosis. Rather, the whole diagnostic concept should be re-considered.
Molecular imaging (MI) appears as an unavoidable challenge for the future of imaging, because MI is able to characterise cellular and molecular processes and will serve as a guide for new targeted or personalised therapies. However, MI appears as hype for many radiologists because it is too far from clinical practice. In reality, MI is already part of clinical practice using PET and targeted…
Molecular Imaging (MI) emerged in the early 21st Century as a discipline at the junction of molecular biology and in vivo imaging to enable the visualisation of the cellular function and the follow-up of the molecular processes in living organisms. Modalities available for MI encompass MRI, CT and ultrasound, PET, as well as Optical Imaging, and are by nature frequently experimental.
A leading radiologist is forecasting a ‘paradigm shift’ in breast imaging. Dr Peter Brader, from Department of Radiology, Division for Molecular and Gender Imaging, Medical University Vienna, envisages that diagnosis and treatment will move from a ‘one size fits all’ approach to one of personalised molecular medicine by 2025. He also foresees greater use of theranostics with combinations…
This one-day symposium will expose the Europe and Israeli research communities to the latest advanced technologies that provide temporal and spatial information on cell fate from the living organism. This event is open to anyone interested, please feel welcome to attend! Registration is mandatory. Participation is free of charge.
"One size fits all" – the phrase is a fact of life in terms of the drugs available to treat cancer patients today. This solution can bear tragic results. Only 25% of cancer patients currently respond to this ‘one size’ drugs administration. In addition, 100,000 patients die annually, in the USA alone, from the side effects of those drugs. Personalised therapies that are devised to suit…
When planning radiotherapy the combination of positron emission tomography (PET) and Computed tomography (CT) can provide a better outcome than CT alone. Michael Krassnitzer asked Terri Bresenham MSc BSc, Vice President for Molecular Imaging at GE Healthcare, for her views on the value of PET/CT, the new EANM guidelines, novel tracers and the future of other hybrid imaging technologies.
High resolution radionuclide imaging is a technique increasingly used to detect breast cancers and has already been shown to offer improved diagnosis in many clinical situations. The technique, which will be discussed at RSNA 2010 (28 November to 3 December, Chicago) , is also allowing clinicians to detect previously unknown areas of breast cancer in women with newly-diagnosed disease.